Wedbush analyst David Nierengarten raised the firm’s price target on Kiniksa (KNSA) to $53 from $50 and keeps an Outperform rating on the shares. The firm notes Arcalyst net product revenue of $202.1M in Q4 and $677.6M for FY25 was in line with the pre-announcement and exceeded its prior estimates, reflecting continued expansion in prescriber breadth and depth alongside longer duration of therapy. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try No ...

LONDON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 3:10 p.m. Eastern Time. A live webcast of Kiniksa’s presentation will be accessible through the Investors section of the company’s website at www.kiniksa.com. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the ...

ARCALYST revenue growth of 62% for full-year 2025 was primarily driven by the expanding adoption of IL-1 alpha and beta inhibition as a second-line treatment immediately following NSAID and colchicine failure. Management attributes commercial success to a fundamental shift in the treatment paradigm, supported by the 2025 ACC clinical guidance which ratified IL-1 inhibition as a preferred second-line approach. The company is leveraging its profitable ARCALYST franchise to fund strategic investments in ...

Kiniksa outlined several commercial priorities for 2026, including physician education and marketing initiatives designed to broaden awareness and support earlier use in the disease course. Moat said the company plans to:Management attributed ARCALYST’s growth primarily to expanding adoption of IL-1 pathway inhibition as a second-line treatment immediately after failure of NSAIDs and colchicine. Moat pointed to the publication of the 2025 ACC Concise Clinical Guidance , which he said recommends IL-1 pathway ...

Rimini Street, Inc. (NASDAQ:RMNI) is a leading provider of enterprise software support services, offering third-party support for major software brands like Oracle and SAP. This approach enables clients to significantly reduce their maintenance costs. In the competitive landscape of software support services, Rimini Street distinguishes itself through its remarkable financial performance and efficient capital utilization.Key Insights:Rimini Street's Return on Invested Capital (ROIC) is 49.18%, substantially ...

Core Viewpoint - Kiniksa Pharmaceuticals will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at 2:15 p.m. Pacific Time [1] Company Overview - Kiniksa is a biopharmaceutical company focused on improving the lives of patients with debilitating diseases by discovering, acquiring, developing, and commercializing novel therapies for unmet medical needs, particularly in cardiovascular indications [3] - The company's portfolio is based on strong biological rationale or validated mechanisms, offering potential for differentiation in the market [3] Event Details - A live webcast of Kiniksa's presentation will be available on the company's website, with a replay accessible approximately 48 hours after the event [2]

Core Insights - Kiniksa Pharmaceuticals International (NASDAQ:KNSA) is identified as a promising mid-cap healthcare stock with a current price under $50, showing potential for growth [1] - Analyst Eva Fortea Verdejo from Wells Fargo has assigned a Buy rating with a price target of $45, indicating a potential increase of 15.77% from current levels [1] - The company is conducting a Phase 2 clinical study on KPL-387 monotherapy aimed at patients with recurrent pericarditis, with a follow-up phase extending over 24 months [2][3] - Successful outcomes from the clinical study could enhance the pipeline value of Kiniksa Pharmaceuticals, attracting investor interest and influencing share price [3] - As of December 19, all 6 analysts covering Kiniksa Pharmaceuticals have assigned Buy ratings, with a consensus 1-year average price target of $52.83, suggesting a 22.3% upside potential [4] - Kiniksa Pharmaceuticals is a biopharmaceutical company focused on developing therapeutic medicines for chronic debilitating diseases, particularly in cardiovascular conditions [5]

Company Overview - Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company focused on improving the lives of patients with debilitating diseases by discovering, acquiring, developing, and commercializing novel therapies for diseases with unmet needs, particularly in cardiovascular indications [3] Upcoming Event - Kiniksa management will present at the Jefferies Global Healthcare Conference in London on November 17, 2025, at 2:30 p.m. GMT (9:30 a.m. ET) [1] - A live webcast of the presentation will be available on Kiniksa's website, with a replay accessible approximately 48 hours after the event [2]

Group 1 - Equinox Gold (EQX) has been added to the Zacks Rank 5 (Strong Sell) List, with a downward revision of almost 26.5% in the consensus estimate for its current year earnings over the last 60 days [1] - Golden Entertainment (GDEN) is also on the Zacks Rank 5 (Strong Sell) List, experiencing a 16.2% downward revision in the consensus estimate for its current year earnings over the last 60 days [2] - Kiniksa Pharmaceuticals International, plc (KNSA) has been included in the Zacks Rank 5 (Strong Sell) List, with a nearly 15.2% downward revision in the consensus estimate for its current year earnings over the last 60 days [3]

Core Insights - Genmab A/S (GMAB) shares have increased by 21.9% over the past month following the announcement of its acquisition of Merus N.V. (MRUS) for $97 per share, totaling approximately $8 billion [1][6] - The acquisition price represents a 41% premium over Merus' closing price of $68.89 on September 26, 2025, with the deal expected to close in early Q1 2026, pending customary conditions [2][3] Company Strategy - The acquisition of Merus signifies Genmab's strategic transition from a licensing-based model to a fully owned business framework, aimed at diversifying its revenue streams [3] - The addition of petosemtamab, Merus' lead late-stage oncology candidate, enhances Genmab's proprietary pipeline and aligns with its expertise in antibody therapy development [4][6] Growth Potential - Genmab anticipates multiple new drug launches by 2027 across various oncology indications, bolstering its long-term growth prospects [4] - Petosemtamab is projected to contribute at least $1 billion in annual sales by 2029, with potential for multi-billion-dollar revenue growth in subsequent years [10] Clinical Development - Petosemtamab is currently being evaluated in two phase III studies for head and neck cancer, with interim results expected in 2026 [9] - The candidate has received two Breakthrough Therapy designations from the FDA, indicating its potential as a first-in-class therapy for head and neck cancer [8]